Navigation Links
IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
Date:11/8/2013

SANTA MONICA, Calif., CLEVELAND and CAESAREA, Israel, Nov. 8, 2013 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) announced today that the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, CA, treated its first breast cancer patient using the IceSense3 Cryoablation System in a pilot study evaluating immune responses in patients with operable breast cancer. In this pilot study, patients undergo cryoablation of their breast cancer before surgery and blood draws at their scheduled office visits.

(Photo:  http://photos.prnewswire.com/prnh/20130507/CL09547 )

To understand the immune response, JWCI researchers are studying the make-up of immune cells and factors within the breast cancer and blood after cryoablation. It is hoped that understanding the immune response elicited by cryoablation will provide information on the mechanisms important for the development of tumor immunity.

"We are excited about this study and the knowledge we will gain regarding how cancers evade the immune system and mechanisms to overcome this resistance," said Maureen Chung, MD, PhD, FACS, Director of Saint John's Margie Petersen Breast Center and JWCI's Margie and Robert E. Petersen Breast Cancer Research Program. "Among several criteria to be eligible for this study, patients must be candidates for breast cancer surgery and the cancer must be visible by ultrasound."

This clinical trial is supported in part by funds donated by the Fashion Footwear Association of New York Charitable Foundation. IceCure neither sponsors nor funds this clinical trial.

"One of our goals is to support investigator-initiated studies of cryoablation in cancer and data collection, which is the first step in potentially making cryoablation available for the treatment of cancer," stated Hezi Himelfarb, President and CEO of IceCure Medical.

Cryoablation is the technique of using extreme cold to destroy tissue. It has been used for years in medical applications such as dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors. The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA-approval for benign and malignant disease.

About John Wayne Cancer Institute
Since 1981, the John Wayne name has been committed by the Wayne family to groundbreaking cancer research and education in memory of their father, who died of cancer. The John Wayne Cancer Institute has received worldwide acclaim for advances in melanoma (skin cancer), breast and colon cancer as well as for immune therapy of cancer. Other areas of research include prostate and liver cancer. With its unique ability to rapidly turn scientific breakthroughs into innovative approaches to treatment and early detection, the Institute provides immediate hope to cancer patients around the globe. For more information, visit www.jwci.org.

About Saint John's Health Center
Since its founding in 1942 by the Sisters of Charity of Leavenworth, Saint John's Health Center has been providing the patients and families of Santa Monica, West Los Angeles and ocean communities with breakthrough medicine and inspired healing. Saint John's provides a spectrum of treatment and diagnostic services with distinguished areas of excellence in cancer care, spine, orthopedics, women's health, cardiac care and specialized programs such as the internationally acclaimed John Wayne Cancer Institute. Saint John's is dedicated to bringing to the community the most innovative advances in medicine and technology. For more information, visit us at www.newstjohns.org, like us at www.facebook.com/NewSaintJohns or follow us at www.twitter.com/SaintJohns2.

About IceCure Medical
IceCure Medical, is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit www.icecure-medical.com.Contact:

Sarah Phelan

Will IrbySaint John's/JWCI

IceCure Medical, Inc.(310) 315-4054

(901) 237-4630(818) 929-4784 (cell)

wirby@icecure-medical.comsarah.phelan@stjohns.org 


'/>"/>
SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
2. Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
3. Quest International Appointed As Authorized Reseller For Sony Electronics Medical Systems Division
4. Call for Entries - 2014 Medical Design Excellence Awards
5. Aethlon Medical to Present at SeeThruEquity Investor Conference
6. Ariosa Diagnostics Appoints Dan Puckett as Chief Financial Officer and Dr. Thomas Musci as Chief Medical Officer
7. Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. Quantum Materials Engineers Tetrapod Quantum Dots to Improve Diagnostic Accuracy of Biomedical Assays and Devices
9. NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
10. Paxeramed debuts industrys first social-media medical images sharing module
11. Cantel Medical Acquires Jet Prep Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  Directors from Pharma To Market Pty Ltd and ... forces, resulting in the founding of Pharma To Market Pte Ltd, ... Market are pleased to announce their expansion into Asia ... Singapore . The company are delighted to appoint Joelle ... Singapore based entity. Joelle brings with her ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... Miami, Florida (PRWEB) , ... February 26, 2017 ... ... disease (PD) patients after receiving cognitive rehabilitation, according to a study released today ... already known that cognitive rehabilitation programs are proven to be effective in improving ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, and ... that 47 percent of all jobs in the United States may be taken over ... day of the aggressive know-it-all who steamrolls over colleagues is drawing to a close. ...
Breaking Medicine News(10 mins):